Stockscreener 앱 받기
1.19
0.00%
0.00
시간 외 거래:
1.19
전일 마감가:
$1.19
열려 있는:
$1.21
하루 거래량:
95,904
Relative Volume:
1.24
시가총액:
$28.14M
수익:
-
순이익/손실:
$-22.29M
주가수익비율:
-1.0085
EPS:
-1.18
순현금흐름:
$-17.12M
1주 성능:
-7.03%
1개월 성능:
+9.17%
6개월 성능:
+0.00%
1년 성능:
-12.18%
1일 변동 폭
$1.18
$1.235
1주일 범위
$1.16
$1.31
52주 변동 폭
$0.8101
$1.76
엔라이벡스 Stock (ENLV) Company Profile
ENLV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.19 | 30.53M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Enlivex Therapeutics Ltd. Stock Analysis and ForecastConsistently high yield - Autocar Professional
What drives Enlivex Therapeutics Ltd. stock priceOutstanding capital returns - Autocar Professional
What analysts say about Enlivex Therapeutics Ltd. stockExtraordinary market timing - Autocar Professional
Is Enlivex Therapeutics Ltd. a good long term investmentRapid return acceleration - Autocar Professional
why enlivex therapeutics ltd. stock attracts strong analyst attentionLow Risk Entry Points - Newser
Why Enlivex Therapeutics Ltd. stock attracts strong analyst attentionReal Trader Insights - beatles.ru
How Enlivex Therapeutics Ltd. stock performs during market volatilityPrecision Entry Strategy - Newser
What makes Enlivex Therapeutics Ltd. stock price move sharplyReturn Maximized Portfolio Strategy - Newser
Sepsis Market Growth to Accelerate in Forecast Period - openPR.com
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
Trust Consulting Services CEO James Radford Named One of CIO Bulletin's "Best Entrepreneurs to Watch 2025" - Marco Eagle
Unusual Machines Announces Termination of Definitive Agreement to Acquire Aloft - The Holland Sentinel
Safe 'N' Sound Environmental Services Ltd. Recognized with 2025 Consumer Choice Award for Asbestos Removal in Halton Region - Sarasota Herald-Tribune
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Enlivex Therapeutics (ENLV) to Present Promising Allocetra Data at EULAR Congress | ENLV Stock News - GuruFocus
Enlivex Therapeutics to Present Clinical Data of Allocetra in Os - GuruFocus
Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona - Nasdaq
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - The Manila Times
Breakthrough Cell Therapy Shows Promise in Knee Osteoarthritis: Enlivex Phase I/II Trial Data at EULAR 2025 - Stock Titan
Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions - Reno Gazette Journal
Millennium Management LLC Acquires New Holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - El Paso Times
Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud
Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times
ENLIVEX THERAPEUTICS Earnings Preview: Recent $ENLV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Enlivex (ENLV) to Present Cell Therapy Advancements at Israeli B - GuruFocus
Revolutionary Cell Therapy Shows 47% Pain Reduction in Osteoarthritis: Enlivex Reveals Breakthrough Data - Stock Titan
Enlivex Selected to Present at Israeli BioMed 2025 Conference - TradingView
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers - Barchart.com
Renaissance Technologies LLC Acquires 84,203 Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus
Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World ... - Bluefield Daily Telegraph
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView
Game-Changing Cell Therapy Helps Patients Avoid Knee Replacement: Clinical Trial Results Revealed - Stock Titan
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):